NFAT 133
Alternative Names: NFAT 33Latest Information Update: 29 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Fatty alcohols; Immunotherapies; Pentanones
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Transplant rejection
Most Recent Events
- 29 Jan 2013 Discontinued - Preclinical for Immunological disorders in USA (unspecified route)
- 29 Jan 2013 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 01 Sep 1998 No development reported - Preclinical for Immunological disorders in USA (unspecified route)